Anti-Gasdermin D (N terminal) Rabbit Polyclonal antibody
Specifications
| Product Cat#: | AB-06-5071 |
| Product type: | Primary antibody |
| Antigen: | Gasdermin D |
| Immunogen: | Recombinant protein within human Gasdermin D aa 100-300. |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot (1:500-1:2000); Immunocytochemistry (1:50-1:100); Immunohistochemistry-Paraffin (1:50-200); Flow Cytometry (1:50-1:100) |
| Reactivity: | Human, Mouse, Rat |
| Clonality (clone number): | Polyclonal |
| Form: | Liquid |
| Buffer: | 1*PBS buffer (pH 7.4), 0.2% BSA, 50% glycerol, 0.05% NaN3. |
| Concentration: | 1 mg/ml |
| Purity: | Immunogen affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | 1810036L03Rik antibody |
| DF 5L antibody | |
| DF5L antibody | |
| DFNA 5L antibody | |
| DFNA5L antibody | |
| FKSG 10 antibody | |
| FKSG10 antibody | |
| FLJ12150 antibody | |
| Gasdermin antibody | |
| Gasdermin D antibody | |
| Gasdermin domain containing 1 antibody | |
| Gasdermin domain containing protein 1 antibody | |
| Gasdermin domain-containing protein 1 antibody | |
| Gasdermin-D antibody | |
| GasderminD antibody | |
| GSDMD antibody | |
| GSDMD_HUMAN antibody | |
| GSDMDC 1 antibody | |
| GSDMDC1 antibody |
Target information
Gasdermin-D, N-terminal
Promotes pyroptosis in response to microbial infection and danger signals (PubMed:26375003, PubMed:26375259, PubMed:27418190, PubMed:28392147, PubMed:32820063).
Produced by the cleavage of gasdermin-D by inflammatory caspases CASP1, CASP4 or CASP5 in response to canonical, as well as non-canonical (such as cytosolic LPS) inflammasome activators (PubMed:26375003, PubMed:26375259, PubMed:27418190).
After cleavage, moves to the plasma membrane where it strongly binds to inner leaflet lipids, including monophosphorylated phosphatidylinositols, such as phosphatidylinositol 4-phosphate, bisphosphorylated phosphatidylinositols, such as phosphatidylinositol (4,5)-bisphosphate, as well as phosphatidylinositol (3,4,5)-bisphosphate, and more weakly to phosphatidic acid and phosphatidylserine (PubMed:27281216, PubMed:29898893).
Homooligomerizes within the membrane and forms pores of 10-15 nanometers (nm) of inner diameter, allowing the release of mature interleukin-1 (IL1B and IL18) and triggering pyroptosis (PubMed:27418190, PubMed:27281216, PubMed:29898893, PubMed:33883744).
Gasdermin pores also allow the release of mature caspase-7 (CASP7) (By similarity).
Exhibits bactericidal activity (PubMed:27281216).
Gasdermin-D, N-terminal released from pyroptotic cells into the extracellular milieu rapidly binds to and kills both Gram-negative and Gram-positive bacteria, without harming neighboring mammalian cells, as it does not disrupt the plasma membrane from the outside due to lipid-binding specificity (PubMed:27281216).
Under cell culture conditions, also active against intracellular bacteria, such as Listeria monocytogenes (By similarity).
Also active in response to MAP3K7/TAK1 inactivation by Yersinia toxin YopJ, which triggers cleavage by CASP8 and subsequent activation (By similarity).
Strongly binds to bacterial and mitochondrial lipids, including cardiolipin (PubMed:27281216).
Does not bind to unphosphorylated phosphatidylinositol, phosphatidylethanolamine nor phosphatidylcholine (PubMed:27281216).
Gasdermin-D
Precursor of a pore-forming protein that plays a key role in host defense against pathogen infection and danger signals (PubMed:26375003, PubMed:26375259, PubMed:27281216).
This form constitutes the precursor of the pore-forming protein: upon cleavage, the released N-terminal moiety (Gasdermin-D, N-terminal) binds to membranes and forms pores, triggering pyroptosis (PubMed:26375003, PubMed:26375259, PubMed:27281216).
Provider
Erpantech Laboratory
